Cytokinetics (CYTK) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $68.78 -1.63%
EPS Growth %: +43.1%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +43.1%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($0.51), in-line with the analyst estimate of ($0.51). Revenue for the quarter came in at $6.22 million versus the consensus estimate of $5.19 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Corpay agrees to $100M FTC settlement over marketing practices
- Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
